Therefore, increasing the number of NK cells in vivo will be crucial to establish combined therapy using Tmab and αCD137 mAb for the treatment of HER2-low-expressing human pancreatic cancer. This evidence concerns the gene ERBB2 and pancreatic neoplasm.